Large Molecule Patents
Tysabri is a drug owned by Biogen Inc.. It is protect by 32 US patents. Given below is the list of those patents along with their expiration dates.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10844416 | BIOGEN INC. | Manganese supplementation for control of glycosylation in mammalian cell culture process |
Jun, 2036
(11 years from now) | Active |
| US11268119 | BIOGEN INC. | Copper supplementation for control of glycosylation in mammalian cell culture process |
Feb, 2036
(11 years from now) | Active |
| US11124760 | BIOGEN INC. | Methods for overcoming glutamine deprivation during mammalian cell culture |
Aug, 2035
(10 years from now) | Active |
| US10023831 | BIOGEN INC. | Gas delivery devices and associated systems and methods |
Mar, 2035
(10 years from now) | Active |
| US10676772 | BIOGEN INC. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
Aug, 2034
(9 years from now) | Active |
| US9994968 | BIOGEN INC. | Electrochemical etching apparatus |
Aug, 2034
(9 years from now) | Active |
| US10119976 | BIOGEN INC. | Method of assessing risk of PML |
May, 2034
(9 years from now) | Active |
| US10677803 | BIOGEN INC. | Method of assessing risk of PML |
May, 2034
(9 years from now) | Active |
| US11280794 | BIOGEN INC. | Method of assessing risk of PML |
May, 2034
(9 years from now) | Active |
| US9562252 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
May, 2033
(8 years from now) | Active |
| US10590454 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
May, 2032
(7 years from now) | Active |
| US9790533 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
May, 2032
(7 years from now) | Active |
| US9316641 | BIOGEN INC. | Assay for JC virus antibodies |
Jan, 2032
(7 years from now) | Active |
| US9109015 | BIOGEN INC. | Method of isolating biomacromolecules using low pH and divalent cations |
Aug, 2031
(6 years from now) | Active |
| US8809049 | BIOGEN INC. | Methods for producing mammalian cells |
May, 2031
(6 years from now) | Active |
| US10308706 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
Feb, 2031
(6 years from now) | Active |
| US8318416 | BIOGEN INC. | Nutrient monitoring and feedback control for increased bioproduct production |
Jan, 2031
(6 years from now) | Active |
| US10444234 | BIOGEN INC. | Assay for JC virus antibodies |
Jan, 2031
(6 years from now) | Active |
| US11287423 | BIOGEN INC. | Assay for JC virus antibodies |
Jan, 2031
(6 years from now) | Active |
| US9096879 | BIOGEN INC. | Method of supplementing culture media to prevent undesirable amino acid substitutions |
Jan, 2031
(6 years from now) | Active |
| US9212379 | BIOGEN INC. | Nutrient monitoring and feedback control for increased bioproduct production |
Nov, 2030
(6 years from now) | Active |
| US9005926 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
Oct, 2030
(5 years from now) | Active |
| US9696307 | BIOGEN INC. | Methods for the detection of JC polyoma virus |
Feb, 2030
(5 years from now) | Active |
| US8124350 | BIOGEN INC. | Methods and products for evaluating an immune response to a therapeutic protein |
Aug, 2027
(2 years from now) | Active |
| US9493567 | BIOGEN INC. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
Mar, 2027
(2 years from now) | Active |
| US10233245 | BIOGEN INC. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
Feb, 2027
(2 years from now) | Active |
| US11292845 | BIOGEN INC. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
Feb, 2027
(2 years from now) | Active |
| US8871449 | BIOGEN INC. | Methods and products for evaluating an immune response to a therapeutic protein |
Apr, 2026
(1 year, 4 months from now) | Active |
| US10705095 | BIOGEN INC. | Methods and products for evaluating an immune response to a therapeutic protein |
Apr, 2026
(1 year, 4 months from now) | Active |
| US9709575 | BIOGEN INC. | Methods and products for evaluating an immune response to a therapeutic protein |
Apr, 2026
(1 year, 4 months from now) | Active |
| US7157276 | BIOGEN INC. | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
Jun, 2024
(4 months ago) |
Expired |
| US7759117 | BIOGEN INC. | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
Jun, 2024
(4 months ago) |
Expired |
Tysabri's Family Patents
Explore Our Curated Drug Screens
About Tysabri
Active Ingredients:
Approval Date:
Dosage:
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 300MG/15ML (20MG/ML) | Injection | Rx | Intravenous |
| 300MG/15ML (20MG/ML) | Injection | Rx | Intravenous |
| 300MG/15ML (20MG/ML) | Injection | Rx | Intravenous |